NovaBay Pharma ( (NBY) ) has released a notification of late filing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
NovaBay Pharmaceuticals, Inc. has announced a delay in filing its Form 10-K (Yearly Report) for the fiscal year ending December 31, 2024. The delay is primarily due to the need for additional time to gather necessary information and complete certain processes and closing procedures. The company expects to file the report within the 15-day extension period provided by the SEC. NovaBay has indicated that no significant changes in financial results are anticipated compared to the previous fiscal year. The notification was signed by Justin M. Hall, the company’s CEO, General Counsel, and Director, who emphasized ongoing compliance efforts.
More about NovaBay Pharma
YTD Price Performance: -5.65%
Average Trading Volume: 209,965
Technical Sentiment Signal: Strong Buy
Current Market Cap: $3.54M
See more insights into NBY stock on TipRanks’ Stock Analysis page.